Andreu Llorente

Assays of different aspects of haemostasis – what do they measure?

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma

Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent

Melioidosis

Perspectives on cancer therapy-induced mucosal injury

Randomized phase II study of biweekly CHOP anddose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin’s lymphoma: Japan Clinical Oncology Group Study 9505

The molecular biology of head and neck cancer

Vascular endothelial growth factor signaling in acute myeloid leukemia

Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation

Non-culture-based methods to diagnose bloodstream infection: Does it work?

Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review

Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Satellite Cells and the Muscle Stem Cell Niche

Hematopoietic contribution to skeletal muscle regeneration by myelomonocytic precursors

Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy‐coats: a retrospective analysis of count increment, corrected count increment and transfusion interval

Enhanced myeloid specificity of CD 117 compared with CD13 and CD33

Neutrophil CD64 expression as marker of bacterial infection: A systematic review and meta-analysis

CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia